Sutro Biopharma Inc (DE:S090)
FRANKFURT:S090
S090 Stock Chart & Stats
€24.20
--
Market closed
€24.20
--
Day’s Range― - ―
52-Week Range€5.58 - €36.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€387.83M
Enterprise Value€188.34M
Total Cash (Recent Filing)€202.56M
Total Debt (Recent Filing)€13.63M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Aug 10, 2026EPS Estimate
-1.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.49
Shares Outstanding16,570,438
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.74
Price to Sales (P/S)0.96
P/FCF Ratio-0.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€41.71Price Target Upside72.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-7.72
Revenue Forecast (FY)€35.53M
Bulls Say, Bears Say
Bulls Say
Proprietary Cell-free Protein Synthesis PlatformSutro’s XpressCF cell‑free platform is a durable competitive asset that speeds protein design and manufacturing iterations. That technical differentiation supports both internal ADC discovery and recurring collaboration/licensing revenue, raising long‑term development efficiency and partner appeal.
Very High Gross Margins (~98% TTM)Gross margins near 98% indicate the platform and service economics are highly scalable. If Sutro converts more collaborations into ongoing programs or commercial products, incremental revenue is likely high margin, improving the long‑run path to positive operating leverage as fixed R&D costs are spread.
Partnerships, Milestone Progress And Strengthened RunwayRecent partner milestones and clinic entries validate the platform and generate non‑dilutive cash; the $110M equity raise plus ATM termination materially extends runway and reduces ongoing dilution risk, enabling Sutro to fund multiple clinical programs and maintain partner momentum over the next 2–3 years.
Bears Say
Severe Cash Burn And Negative Operating Cash FlowSustained ~-$150M annual cash burn forces reliance on external financing to sustain R&D and trials. Even with recent financing, continued negative operating cash flow reduces flexibility, increases dilution risk if milestones slip, and makes multi‑period program funding contingent on future raises or partner payments.
Negative Stockholders' EquityNegative equity reflects cumulative losses exceeding capital and weakens the balance sheet. This elevates solvency and counterparty concerns, can limit borrowing capacity or favorable partner terms, and reduces financial flexibility during extended clinical development cycles or unexpected setbacks.
Large Operating Losses And Volatile RevenueDeep operating losses and a highly volatile top line show reliance on lumpy collaboration payments rather than steady product revenue. This unpredictability complicates multi‑period planning, elevates execution risk for sustaining R&D spend, and makes the path to durable profitability uncertain without consistent partner deals or product approvals.
Sutro Biopharma News
S090 FAQ
What was Sutro Biopharma Inc’s price range in the past 12 months?
Sutro Biopharma Inc lowest stock price was €5.58 and its highest was €36.00 in the past 12 months.
What is Sutro Biopharma Inc’s market cap?
Sutro Biopharma Inc’s market cap is €387.83M.
When is Sutro Biopharma Inc’s upcoming earnings report date?
Sutro Biopharma Inc’s upcoming earnings report date is Aug 10, 2026 which is in 66 days.
How were Sutro Biopharma Inc’s earnings last quarter?
Sutro Biopharma Inc released its earnings results on May 14, 2026. The company reported -€2.522 earnings per share for the quarter, missing the consensus estimate of -€2.347 by -€0.175.
Is Sutro Biopharma Inc overvalued?
According to Wall Street analysts Sutro Biopharma Inc’s price is currently Undervalued.
Does Sutro Biopharma Inc pay dividends?
Sutro Biopharma Inc does not currently pay dividends.
What is Sutro Biopharma Inc’s EPS estimate?
Sutro Biopharma Inc’s EPS estimate is -1.86.
How many shares outstanding does Sutro Biopharma Inc have?
Sutro Biopharma Inc has 16,570,438 shares outstanding.
What happened to Sutro Biopharma Inc’s price movement after its last earnings report?
Sutro Biopharma Inc reported an EPS of -€2.522 in its last earnings report, missing expectations of -€2.347. Following the earnings report the stock price went up 3.145%.
Which hedge fund is a major shareholder of Sutro Biopharma Inc?
Currently, no hedge funds are holding shares in DE:S090
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sutro Biopharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.84%
12-Months-Change
Fundamentals
Return on Equity
275.30%
Trailing 12-Months
Asset Growth
-24.72%
Trailing 12-Months
Company Description
Sutro Biopharma Inc
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
S090 Stock 12 Month Forecast
Average Price Target
€41.71
▲(72.34% Upside)
Options Prices
Currently, No data available
---